After a series of negative earnings surprises, the Q1 results exceeded our expectations, mainly on progress in the key Consumer Packaging division. In addition, we found it reassuring that management reiterated that the forestry asset sale is ongoing, with completion expected before end-H1. We have made limited forecast changes, and reiterate our BUY and EUR12 target price.
We reiterate our BUY and EUR11 target price, with only small estimate changes following the Q1 results (which brought stronger orders but softer earnings than we expected). Despite general uncertainties, we continue to view Metso’s end-market exposure, financials and valuation as attractive.
Reflecting escalating general macro uncertainty leading to softer prices for most of Stora Enso’s industries and FX headwinds (weaker USD and stronger SEK), we have reduced our 2025–2026e adj. EBITDA by 6% per year. Despite this, we still find the valuation discount too high, especially since we believe Stora Enso’s explicit plan of selling 12% of its Swedish forestland could be a potential positive catalyst. We reiterate our BUY, but have reduced our target price to EUR12 (13).
Three Directors at BioArctic AB bought 3,120 shares at between 163.200SEK and 164.700SEK. The significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.